Literature DB >> 16493628

Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation.

K Spencer1, C K H Yu, M Savvidou, A T Papageorghiou, K H Nicolaides.   

Abstract

OBJECTIVE: To investigate the potential value of combining uterine artery Doppler ultrasonography with the measurement of maternal serum pregnancy-associated plasma protein-A (PAPP-A), free beta-human chorionic gonadotropin (beta-hCG), activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation, in the prediction of pregnancies that subsequently develop pre-eclampsia.
METHODS: The maternal serum PAPP-A, free beta-hCG, activin A and inhibin A concentrations at 22 + 0 to 24 + 6 weeks' gestation were measured in samples obtained from women with singleton pregnancies who participated in a screening study for pre-eclampsia by transvaginal color flow Doppler measurement of the uterine artery pulsatility index (PI). A search was made of the database to identify those who subsequently developed pre-eclampsia (n = 24) and a group of controls with normal outcome (n = 144). Regression analysis was performed to establish any relationship between the biochemical markers themselves and between the biochemical markers and uterine artery mean PI. A multivariate Gaussian model combining various biochemical markers with uterine artery mean PI was developed using standard statistical modeling techniques and the performance of such models in discriminating cases with pre-eclampsia was evaluated by receiver-operating characteristics curve (ROC) analysis.
RESULTS: In the pre-eclampsia group, compared to the controls, the uterine artery mean PI and the maternal serum levels of PAPP-A, free beta-hCG, activin A and inhibin A were significantly increased. The predicted detection rates of pre-eclampsia, for a false positive rate of 5%, was 50% by uterine artery mean PI, 5% by PAPP-A, 10% by free beta-hCG, 35% by inhibin A and 44% by activin A. Screening by a combination of uterine artery mean PI and maternal serum activin A and inhibin A could detect 75% and 92% of patients who subsequently developed pre-eclampsia, for false positive rates of 5% and 10%, respectively.
CONCLUSION: Screening for pre-eclampsia by uterine artery PI at 22 + 0 to 24 + 6 weeks' gestation can be improved by measurement of activin A and inhibin A levels. Copyright 2006 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493628     DOI: 10.1002/uog.2676

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  13 in total

Review 1.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

2.  Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.

Authors:  Nandor Gabor Than; Roberto Romero; Adi Laurentiu Tarca; Katalin Adrienna Kekesi; Yi Xu; Zhonghui Xu; Kata Juhasz; Gaurav Bhatti; Ron Joshua Leavitt; Zsolt Gelencser; Janos Palhalmi; Tzu Hung Chung; Balazs Andras Gyorffy; Laszlo Orosz; Amanda Demeter; Anett Szecsi; Eva Hunyadi-Gulyas; Zsuzsanna Darula; Attila Simor; Katalin Eder; Szilvia Szabo; Vanessa Topping; Haidy El-Azzamy; Christopher LaJeunesse; Andrea Balogh; Gabor Szalai; Susan Land; Olga Torok; Zhong Dong; Ilona Kovalszky; Andras Falus; Hamutal Meiri; Sorin Draghici; Sonia S Hassan; Tinnakorn Chaiworapongsa; Manuel Krispin; Martin Knöfler; Offer Erez; Graham J Burton; Chong Jai Kim; Gabor Juhasz; Zoltan Papp
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

3.  Evaluation of Serum Pregnancy Associated Plasma Protein-A & Plasma D-Dimer in Acute Coronary Syndrome.

Authors:  Gautam Nichenametla; Vivian Samuel Thomas
Journal:  J Clin Diagn Res       Date:  2016-01-01

4.  Predicting the risk of pre-eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free β-hCG.

Authors:  Katherine R Goetzinger; Ashima Singla; Sabrina Gerkowicz; Jeffrey M Dicke; Diana L Gray; Anthony O Odibo
Journal:  Prenat Diagn       Date:  2010-12       Impact factor: 3.050

5.  First-trimester serum analytes, biophysical tests and the association with pathological morphometry in the placenta of pregnancies with preeclampsia and fetal growth restriction.

Authors:  A O Odibo; Y Zhong; M Longtine; M Tuuli; L Odibo; A G Cahill; G A Macones; D M Nelson
Journal:  Placenta       Date:  2011-02-13       Impact factor: 3.481

6.  Placental elastography in second trimester preeclampsia prediction: A prospective study.

Authors:  Rajkumar Meena; Amita Malik; Swarna Jain; Achla Batra
Journal:  Ultrasound       Date:  2021-09-10

7.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

Review 8.  Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis.

Authors:  Rachel K Morris; Jeltsje S Cnossen; Marloes Langejans; Stephen C Robson; Jos Kleijnen; Gerben Ter Riet; Ben W Mol; Joris A M van der Post; Khalid S Khan
Journal:  BMC Pregnancy Childbirth       Date:  2008-08-04       Impact factor: 3.007

9.  Preeclampsia: a bioinformatics approach through protein-protein interaction networks analysis.

Authors:  Eduardo Tejera; João Bernardes; Irene Rebelo
Journal:  BMC Syst Biol       Date:  2012-08-08

10.  Predictive Performance of Serum β-hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis.

Authors:  Xiao Zhang; Zhao Huangfu; Fangxin Shi; Zhen Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.